DGpeptides

DGpeptides is a clinical-stage biotechnology company focused on the development of oral peptide therapeutics, primarily targeting metabolic diseases. The company leverages its proprietary DG-Oral delivery technology to enable the oral administration of peptides that are typically delivered via injection, such as GLP-1 receptor agonists. Its lead program, DG-001, is an oral GLP-1R agonist designed for the treatment of type 2 diabetes and obesity. By improving patient compliance and accessibility, DGpeptides seeks to address significant unmet needs in the management of chronic metabolic conditions. The company is headquartered in Hangzhou, China, and is supported by leading venture capital investors.